Below you can access the latest educational webinars organised by Novartis and hosted by experts in the field of neuroscience. You will find full recordings, enabling you to listen to the webinars at a time that is convenient for you.
You will be required to register to watch the videos.
Developing a MAYZENT (siponimod) patient pathway for your MS service
Watch Dr Wallace Brownlee and Ms Joela Mathews discuss the importance of DMT pathways and share the MAYZENT protocol for patients with SPMS with active disease, using specific patient cases to exemplify how the process can be implemented within local MS services.
MAYZENT is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.1
DMT, disease-modifying therapy; MS, multiple sclerosis; SPMS, secondary progressive multiple sclerosis.
1. MAYZENT (siponimod) Summary of Product Characteristics.